FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4224879897> ?p ?o ?g. }

• W4224879897 endingPage "S49" @default.
• W4224879897 startingPage "S48" @default.
• W4224879897 abstract "ABSTRACT Introduction Anabolic-androgenic steroids (AAS), synthetic derivatives of the male sex hormone testosterone, are often used to enhance athletic performance and physical appearance. Long term use of AAS can be associated with mood destabilizing effects and psychotic behavior. We hypothesized that AAS use is an independent risk factor for mental health disorders. We investigated AAS use and associations with major depressive disorder (MDD), suicide attempt (SA)/intentional self-harm (ISH), and body dysmorphic disorder (BDD) by querying TriNetX, a global health research network that provides data on large cohort of patients from multiple centers across the United States. Objective To determine the association between AAS use with MDD, SA/ISH, and BDD. Methods To evaluate the psychiatric risk of AAS use two cohorts of adult men, aged 18-50, without history of gender dysphoria (F64, Z87.890) (1) history of documented AAS use, inclusive of testosterone prescriptions (2) history of a visit to a healthcare organization and no history of AAS use. We accounted for confounding variables known to be associated with a risk of mood disorders through propensity score matching by logistic regression for age, race, ethnicity, male hypogonadism (E29.1), history of nicotine dependence (Z87.891), or alcohol-related disorder (F10). We evaluated the association between steroid use and subsequent diagnosis of MDD (F32-33), SA/ISH (T14.91, X71-83, T36-65 and T71 ISH codes), or BDD (F45.22) as a primary outcome through regression analysis with statistical significance assessed at p&lt;.05. Results We identified 159,717 cis-men between age 18-50 who used AAS and following propensity score matching for confounding variables, we compared them to an equal-sized cohort of men without AAS use. AAS use was independently associated with all of the psychiatric outcomes that we studied (MDD OR 2.96 95% CI 2.88-3.04 p&lt;.0001, SA/ISH OR 1.37 95% CI 1.25-1.50 p&lt;.0001, BDD OR 5.37 95% CI 2.82-10.21 p&lt;.0001). Strengths of the study include a large sample size, propensity score matching to adjust for confounding variables, and high strength of association. Limitations include lack of information regarding indication for steroid prescription or details regarding severity, duration, withdrawal, or possible steroid abuse. Conclusions AAS use appears to be an independent risk factor for MDD, BDD, and/or SA/ISH. Future studies are necessary to elucidate whether a dose-response association exists, withdrawal from AAS plays a role, and if patient selection or preventative measures can mitigate the risk. Men with suicide attempt, BDD, or MDD should be investigated for a history of AAS use. Further, men receiving AAS should be counseled on the possible risk of developing MDD in the future. AAS use can lead to profound and complex psychiatric complications which should be discussed in patient counseling. Disclosure No" @default.
• W4224879897 created "2022-04-27" @default.
• W4224879897 creator A5003638019 @default.
• W4224879897 creator A5024679071 @default.
• W4224879897 creator A5025348800 @default.
• W4224879897 creator A5039179976 @default.
• W4224879897 creator A5079261289 @default.
• W4224879897 date "2022-04-01" @default.
• W4224879897 modified "2023-09-26" @default.
• W4224879897 title "94 Anabolic-Androgenic Steroid Use is Associated with Major Depressive Disorder and Suicide Attempt: Analysis of a Multi-National Database" @default.
• W4224879897 doi "https://doi.org/10.1016/j.jsxm.2022.01.106" @default.
• W4224879897 hasPublicationYear "2022" @default.
• W4224879897 type Work @default.
• W4224879897 citedByCount "0" @default.
• W4224879897 crossrefType "journal-article" @default.
• W4224879897 hasAuthorship W4224879897A5003638019 @default.
• W4224879897 hasAuthorship W4224879897A5024679071 @default.
• W4224879897 hasAuthorship W4224879897A5025348800 @default.
• W4224879897 hasAuthorship W4224879897A5039179976 @default.
• W4224879897 hasAuthorship W4224879897A5079261289 @default.
• W4224879897 hasConcept C118552586 @default.
• W4224879897 hasConcept C126322002 @default.
• W4224879897 hasConcept C15744967 @default.
• W4224879897 hasConcept C185592680 @default.
• W4224879897 hasConcept C2776641880 @default.
• W4224879897 hasConcept C2777134132 @default.
• W4224879897 hasConcept C2779279991 @default.
• W4224879897 hasConcept C2779442783 @default.
• W4224879897 hasConcept C2780051608 @default.
• W4224879897 hasConcept C2780733359 @default.
• W4224879897 hasConcept C2780842732 @default.
• W4224879897 hasConcept C2781066024 @default.
• W4224879897 hasConcept C3017944768 @default.
• W4224879897 hasConcept C526869908 @default.
• W4224879897 hasConcept C55493867 @default.
• W4224879897 hasConcept C558461103 @default.
• W4224879897 hasConcept C70410870 @default.
• W4224879897 hasConcept C71924100 @default.
• W4224879897 hasConcept C72563966 @default.
• W4224879897 hasConcept C77350462 @default.
• W4224879897 hasConcept C99454951 @default.
• W4224879897 hasConceptScore W4224879897C118552586 @default.
• W4224879897 hasConceptScore W4224879897C126322002 @default.
• W4224879897 hasConceptScore W4224879897C15744967 @default.
• W4224879897 hasConceptScore W4224879897C185592680 @default.
• W4224879897 hasConceptScore W4224879897C2776641880 @default.
• W4224879897 hasConceptScore W4224879897C2777134132 @default.
• W4224879897 hasConceptScore W4224879897C2779279991 @default.
• W4224879897 hasConceptScore W4224879897C2779442783 @default.
• W4224879897 hasConceptScore W4224879897C2780051608 @default.
• W4224879897 hasConceptScore W4224879897C2780733359 @default.
• W4224879897 hasConceptScore W4224879897C2780842732 @default.
• W4224879897 hasConceptScore W4224879897C2781066024 @default.
• W4224879897 hasConceptScore W4224879897C3017944768 @default.
• W4224879897 hasConceptScore W4224879897C526869908 @default.
• W4224879897 hasConceptScore W4224879897C55493867 @default.
• W4224879897 hasConceptScore W4224879897C558461103 @default.
• W4224879897 hasConceptScore W4224879897C70410870 @default.
• W4224879897 hasConceptScore W4224879897C71924100 @default.
• W4224879897 hasConceptScore W4224879897C72563966 @default.
• W4224879897 hasConceptScore W4224879897C77350462 @default.
• W4224879897 hasConceptScore W4224879897C99454951 @default.
• W4224879897 hasIssue "Supplement_1" @default.
• W4224879897 hasLocation W42248798971 @default.
• W4224879897 hasOpenAccess W4224879897 @default.
• W4224879897 hasPrimaryLocation W42248798971 @default.
• W4224879897 hasRelatedWork W1975497902 @default.
• W4224879897 hasRelatedWork W1993397976 @default.
• W4224879897 hasRelatedWork W2014156409 @default.
• W4224879897 hasRelatedWork W2016432215 @default.
• W4224879897 hasRelatedWork W2044226656 @default.
• W4224879897 hasRelatedWork W2064607685 @default.
• W4224879897 hasRelatedWork W2083039871 @default.
• W4224879897 hasRelatedWork W2781642709 @default.
• W4224879897 hasRelatedWork W3173153788 @default.
• W4224879897 hasRelatedWork W3213208972 @default.
• W4224879897 hasVolume "19" @default.
• W4224879897 isParatext "false" @default.
• W4224879897 isRetracted "false" @default.
• W4224879897 workType "article" @default.